Researchers have successfully conducted the first clinical trial using activated regulatory T cells (ATregs, Actileucel)—derived from white blood cells of healthy blood donors. This novel cell therapy aims to prevent graft-versus-host disease (GvHD) following an allogeneic stem cell transplant. The Phase I/II study has yielded extremely encouraging results: ATregs can be produced within 24 hours and injected immediately afterward; administration is safe and well-tolerated by patients—a significant step toward a widely available cell therapy. The research is published in Transplantation and Cellular Therapy.
❓ Unknown
Activated Donor Immune Cells Show Promise in Preventing Complications After Stem Cell Transplantation
Just now
September 20, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
Researchers have conducted a successful clinical trial using activated regulatory T cells derived from healthy donors to prevent graft-versus-host disease after allogeneic stem cell transplants. This breakthrough could lead to a widely available cell therapy, enhancing treatment options for patients. The implications for Iran lie in the potential advancement of medical research and healthcare capabilities.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
11 min ago •
Accuracy in Census is the Basis for Khuzestan's Development / Population and Housing Census in…
11 min ago •
US Congress Investigates Mysterious Transfer of F-35 Secret Parts to Hong Kong
14 min ago •
Providing 80 Percent of the Rial Equivalent for Currency Transfer for Importing Goods
14 min ago •
Governor Emphasizes Preventive Measures and Acceleration of Watershed Management Projects in Mazandaran
14 min ago •